Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA.
Sign Up to like & getrecommendations! Published in 2025 at "Modern rheumatology"
DOI: 10.1093/mr/roaf037
Abstract: OBJECTIVES To understand the prevalence and characteristics of rheumatoid arthritis (RA) patients not using biologic/targeted synthetic disease-modifying drugs (b/tsDMARDs) despite insufficient disease control. METHODS The data from 3172 RA patients in the FRANK (Fukuoka RA… read more here.
Keywords: disease; rheumatology; rheumatoid arthritis; using biologic ... See more keywords
Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab570
Abstract: OBJECTIVE To estimate the occurrence and relative risks of first ever incident non-cutaneous cancer overall and by 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment… read more here.
Keywords: clinical practice; targeted synthetic; treatment; rheumatology ... See more keywords
National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease-modifying agent users within the Veterans Health Administration.
Sign Up to like & getrecommendations! Published in 2024 at "Health services research"
DOI: 10.1111/1475-6773.14363
Abstract: OBJECTIVE To develop, deploy, and evaluate a national, electronic health record (EHR)-based dashboard to support safe prescribing of biologic and targeted synthetic disease-modifying agents (b/tsDMARDs) in the United States Veterans Affairs Healthcare System (VA). DATA… read more here.
Keywords: dashboard; synthetic disease; disease modifying; biologic targeted ... See more keywords
Clinical Audit of screening Latent TB, Hepatitis-C, and Occult Hepatitis-B in Rheumatoid arthritis’ patients starting biologic or targeted synthetic DMARDS
Sign Up to like & getrecommendations! Published in 2025 at "Pakistan Journal of Medical Sciences"
DOI: 10.12669/pjms.41.6.11427
Abstract: Objective: To highlight the importance of pre-treatment screening in Rheumatoid arthritis’ patients starting biologic or targeted synthetic DMARDS. Methods: This retrospective multicentric clinical audit was conducted at the Department of Rheumatology, Central Park Teaching Hospital… read more here.
Keywords: treatment; rheumatology; hepatitis; clinical audit ... See more keywords
Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Sign Up to like & getrecommendations! Published in 2023 at "PLoS computational biology"
DOI: 10.1371/journal.pcbi.1011073
Abstract: Cycling of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients due to non-response is a problem preventing and delaying disease control. We aimed to assess and validate treatment response… read more here.
Keywords: biologic targeted; rheumatoid arthritis; deep learning; targeted synthetic ... See more keywords